



**SERES**  
THERAPEUTICS™

**Seres Therapeutics to Participate in the Piper Sandler 35th Annual Healthcare Conference on Wednesday, November 29, 2023; Webcast at 3:30 p.m. ET**

November 28, 2023

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Nov. 28, 2023-- [Seres Therapeutics, Inc.](#) (Nasdaq: MCRB), a leading microbiome therapeutics company, today announced that Seres management will participate at the Piper Sandler 35th Annual Healthcare Conference on Wednesday, November 29, 2023, at 3:30 p.m. ET.

An audio webcast of the presentation will be available under the "Investors and News" section of Seres' website. A replay of the presentation will become available approximately one hour after the event and will be archived for approximately 30 days.

**About Seres Therapeutics**

Seres Therapeutics, Inc. (Nasdaq: MCRB) is a commercial-stage company developing novel microbiome therapeutics for serious diseases. Seres' lead program, VOWST™, obtained J.S. FDA approval in April 2023 as the first orally administered microbiome therapeutic to prevent recurrence of C. difficile infection (CDI) in adults following antibacterial treatment for recurrent CDI and is being commercialized in collaboration with Nestlé Health Science. Seres is evaluating SER-155 in a Phase 1b study in patients receiving allogeneic hematopoietic stem cell transplantation. For more information, please visit [www.serestherapeutics.com](http://www.serestherapeutics.com).

View source version on [businesswire.com](https://www.businesswire.com/news/home/20231127059541/en/): <https://www.businesswire.com/news/home/20231127059541/en/>

**Investor and Media:**

Kevin Mannix

[kmannix@serestherapeutics.com](mailto:kmannix@serestherapeutics.com)

Source: Seres Therapeutics, Inc.